Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy

a case report

Flavio Giannelli, Ilaria Chiola, Liliana Belgioia, Stefania Garelli, Alice Pastorino, Michela Marcenaro, Serafina Mammoliti, Sergio Costantini, Nicolò Bizzarri, Valerio Vellone, Salvina Barra, Renzo Corvò

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of hidradenocarcinoma treated with external beam radiotherapy delivered by helical tomotherapy with a simultaneous integrated boost (SIB), followed by brachytherapy. External beam radiotherapy dose prescription was 50.4 Gy in 28 fractions, five fractions per week to whole pelvis (planning target volume 1 – PTV1), 60.2 Gy in 28 fractions to SIB1 (fundus of uterus and right inguinal node), and 58.8 Gy in 28 fractions to SIB2 (lower/middle third of vagina, paraurethral region and right inguinal lymph nodes). Brachytherapy dose prescription was 28 Gy in 4 fractions for cervix, fundus of uterus and upper third of vagina (HR-CTV1), and 22 Gy in 4 fractions to middle third of vagina and paraurethral region (HR-CTV2). D90 for whole treatment was 91.9 Gy and 86.0 Gy for HR-CTV1 and HR-CTV2, respectively. Patient remained 12-months disease-free without treatment related side effects.

Original languageEnglish
Pages (from-to)572-578
Number of pages7
JournalJournal of Contemporary Brachytherapy
Volume9
Issue number6
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Brachytherapy
Vagina
Radiotherapy
Groin
Prescriptions
Intensity-Modulated Radiotherapy
Rare Diseases
Pelvis
Cervix Uteri
Uterus
Therapeutics
Lymph Nodes

Keywords

  • High-dose-rate (HDR) brachytherapy
  • Image-guide radiotherapy (IGRT)
  • Vulvo-vaginal hidradenocarcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy : a case report. / Giannelli, Flavio; Chiola, Ilaria; Belgioia, Liliana; Garelli, Stefania; Pastorino, Alice; Marcenaro, Michela; Mammoliti, Serafina; Costantini, Sergio; Bizzarri, Nicolò; Vellone, Valerio; Barra, Salvina; Corvò, Renzo.

In: Journal of Contemporary Brachytherapy, Vol. 9, No. 6, 01.01.2017, p. 572-578.

Research output: Contribution to journalArticle

Giannelli, Flavio ; Chiola, Ilaria ; Belgioia, Liliana ; Garelli, Stefania ; Pastorino, Alice ; Marcenaro, Michela ; Mammoliti, Serafina ; Costantini, Sergio ; Bizzarri, Nicolò ; Vellone, Valerio ; Barra, Salvina ; Corvò, Renzo. / Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy : a case report. In: Journal of Contemporary Brachytherapy. 2017 ; Vol. 9, No. 6. pp. 572-578.
@article{c31e2e9a441d43c4af16318b5ef8e42c,
title = "Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy: a case report",
abstract = "Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of hidradenocarcinoma treated with external beam radiotherapy delivered by helical tomotherapy with a simultaneous integrated boost (SIB), followed by brachytherapy. External beam radiotherapy dose prescription was 50.4 Gy in 28 fractions, five fractions per week to whole pelvis (planning target volume 1 – PTV1), 60.2 Gy in 28 fractions to SIB1 (fundus of uterus and right inguinal node), and 58.8 Gy in 28 fractions to SIB2 (lower/middle third of vagina, paraurethral region and right inguinal lymph nodes). Brachytherapy dose prescription was 28 Gy in 4 fractions for cervix, fundus of uterus and upper third of vagina (HR-CTV1), and 22 Gy in 4 fractions to middle third of vagina and paraurethral region (HR-CTV2). D90 for whole treatment was 91.9 Gy and 86.0 Gy for HR-CTV1 and HR-CTV2, respectively. Patient remained 12-months disease-free without treatment related side effects.",
keywords = "High-dose-rate (HDR) brachytherapy, Image-guide radiotherapy (IGRT), Vulvo-vaginal hidradenocarcinoma",
author = "Flavio Giannelli and Ilaria Chiola and Liliana Belgioia and Stefania Garelli and Alice Pastorino and Michela Marcenaro and Serafina Mammoliti and Sergio Costantini and Nicol{\`o} Bizzarri and Valerio Vellone and Salvina Barra and Renzo Corv{\`o}",
year = "2017",
month = "1",
day = "1",
doi = "10.5114/jcb.2017.71554",
language = "English",
volume = "9",
pages = "572--578",
journal = "Journal of Contemporary Brachytherapy",
issn = "1689-832X",
publisher = "Termedia Publishing House Ltd.",
number = "6",

}

TY - JOUR

T1 - Complete response in a patient with gynecological hidradenocarcinoma treated with exclusive external beam radiotherapy and brachytherapy

T2 - a case report

AU - Giannelli, Flavio

AU - Chiola, Ilaria

AU - Belgioia, Liliana

AU - Garelli, Stefania

AU - Pastorino, Alice

AU - Marcenaro, Michela

AU - Mammoliti, Serafina

AU - Costantini, Sergio

AU - Bizzarri, Nicolò

AU - Vellone, Valerio

AU - Barra, Salvina

AU - Corvò, Renzo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of hidradenocarcinoma treated with external beam radiotherapy delivered by helical tomotherapy with a simultaneous integrated boost (SIB), followed by brachytherapy. External beam radiotherapy dose prescription was 50.4 Gy in 28 fractions, five fractions per week to whole pelvis (planning target volume 1 – PTV1), 60.2 Gy in 28 fractions to SIB1 (fundus of uterus and right inguinal node), and 58.8 Gy in 28 fractions to SIB2 (lower/middle third of vagina, paraurethral region and right inguinal lymph nodes). Brachytherapy dose prescription was 28 Gy in 4 fractions for cervix, fundus of uterus and upper third of vagina (HR-CTV1), and 22 Gy in 4 fractions to middle third of vagina and paraurethral region (HR-CTV2). D90 for whole treatment was 91.9 Gy and 86.0 Gy for HR-CTV1 and HR-CTV2, respectively. Patient remained 12-months disease-free without treatment related side effects.

AB - Hidradenocarcinoma (HC) is a very rare disease. This case report illustrates a successful treatment of a 60-year-old woman with vulvo-vaginal localization of hidradenocarcinoma treated with external beam radiotherapy delivered by helical tomotherapy with a simultaneous integrated boost (SIB), followed by brachytherapy. External beam radiotherapy dose prescription was 50.4 Gy in 28 fractions, five fractions per week to whole pelvis (planning target volume 1 – PTV1), 60.2 Gy in 28 fractions to SIB1 (fundus of uterus and right inguinal node), and 58.8 Gy in 28 fractions to SIB2 (lower/middle third of vagina, paraurethral region and right inguinal lymph nodes). Brachytherapy dose prescription was 28 Gy in 4 fractions for cervix, fundus of uterus and upper third of vagina (HR-CTV1), and 22 Gy in 4 fractions to middle third of vagina and paraurethral region (HR-CTV2). D90 for whole treatment was 91.9 Gy and 86.0 Gy for HR-CTV1 and HR-CTV2, respectively. Patient remained 12-months disease-free without treatment related side effects.

KW - High-dose-rate (HDR) brachytherapy

KW - Image-guide radiotherapy (IGRT)

KW - Vulvo-vaginal hidradenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85041225592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041225592&partnerID=8YFLogxK

U2 - 10.5114/jcb.2017.71554

DO - 10.5114/jcb.2017.71554

M3 - Article

VL - 9

SP - 572

EP - 578

JO - Journal of Contemporary Brachytherapy

JF - Journal of Contemporary Brachytherapy

SN - 1689-832X

IS - 6

ER -